These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22219230)

  • 41. Serial measurements of plasma B-type natriuretic peptides: what do they tell us?
    Richards AM
    J Am Coll Cardiol; 2008 Sep; 52(12):1004-5. PubMed ID: 18786481
    [No Abstract]   [Full Text] [Related]  

  • 42. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Dong H; Chen DQ; Wang Y; Li M
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison study on diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
    Li YJ; Wang L; Chen KY; Chen YL; Cai JR; Zhou LJ
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Sep; 17(9):544-7. PubMed ID: 16146600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A mechanistic interaction remains to be determined for elevated NTproBNP in heart failure patients receiving both an ACE inhibitor and aspirin.
    McLachlan CS; Zhang Z; Mossop P
    J Card Fail; 2007 Feb; 13(1):75-6. PubMed ID: 17339006
    [No Abstract]   [Full Text] [Related]  

  • 45. N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure.
    O'Donoghue M; Januzzi JL
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):487-96. PubMed ID: 15889976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [CA-125 - does this next biomarker have a chance to hope for an expectation of risk stratification in patients with heart failure?].
    Zieliński T
    Kardiol Pol; 2010 Jul; 68(7):779-80. PubMed ID: 20648435
    [No Abstract]   [Full Text] [Related]  

  • 47. [Pro: Natriuretic peptides as diagnostic tool. The analysis should be a routine in heart failure diagnosis].
    Dahlström U; Alehagen U
    Lakartidningen; 2006 Mar 22-28; 103(12):927-9. PubMed ID: 16618036
    [No Abstract]   [Full Text] [Related]  

  • 48. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients.
    Pfister R; Diedrichs H; Schiedermair A; Rosenkranz S; Hellmich M; Erdmann E; Schneider CA
    Eur J Heart Fail; 2008 Mar; 10(3):315-20. PubMed ID: 18304872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP.
    Shelton RJ; Goode K; Cleland JG
    Europace; 2007 Feb; 9(2):147; author reply 148. PubMed ID: 17227813
    [No Abstract]   [Full Text] [Related]  

  • 50. Exercise-induced biphasic increase in circulating NT-proBNP levels in patients with chronic heart failure.
    Conraads VM; De Maeyer C; Beckers P; Possemiers N; Martin M; Van Hoof V; Vrints CJ
    Eur J Heart Fail; 2008 Aug; 10(8):793-5. PubMed ID: 18599343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.
    Bruch C; Fischer C; Sindermann J; Stypmann J; Breithardt G; Gradaus R
    Am J Cardiol; 2008 Aug; 102(4):469-74. PubMed ID: 18678308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NT-pro-brain natriuretic peptide levels after valve replacement.
    Elasfar AA
    Asian Cardiovasc Thorac Ann; 2011 Dec; 19(6):399-402. PubMed ID: 22160408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial.
    Shah MR; Claise KA; Bowers MT; Bhapkar M; Little J; Nohria A; Gaulden LH; McKee VK; Cozart KL; Mancinelli KL; Daniels H; Kinard T; Stevenson LW; Mancini DM; O'Connor CM; Califf RM
    Am Heart J; 2005 Nov; 150(5):893-8. PubMed ID: 16290955
    [No Abstract]   [Full Text] [Related]  

  • 54. B-type natriuretic peptide as a marker of heart failure: Not so specific after all?
    Marshall W; Orlando R
    Crit Care Med; 2006 Aug; 34(8):2249. PubMed ID: 16883197
    [No Abstract]   [Full Text] [Related]  

  • 55. Analytical performance vs clinical use of natriuretic peptide measurements.
    Andrade DM; Vidigal PG; Eloi-Santos SM
    Arch Intern Med; 2010 Jul; 170(14):1274; author reply 1275. PubMed ID: 20660853
    [No Abstract]   [Full Text] [Related]  

  • 56. [Heart failure. Diagnosis and prognosis readable from a simple blood test].
    MMW Fortschr Med; 2004 Mar; 146(11):59. PubMed ID: 15152779
    [No Abstract]   [Full Text] [Related]  

  • 57. Statins and heart failure.
    Athyros VG; Karagiannis A; Mikhailidis DP
    J Am Coll Cardiol; 2010 Apr; 55(15):1644-5; author reply 1646. PubMed ID: 20378087
    [No Abstract]   [Full Text] [Related]  

  • 58. [Tailored drug therapy in heart failure--a future vision. Biological markers can support individually directed treatment].
    Dahlström U
    Lakartidningen; 2009 Oct 14-20; 106(42):2674-5. PubMed ID: 19967945
    [No Abstract]   [Full Text] [Related]  

  • 59. Paediatric heart failure trials...and tribulations.
    Shaddy RE
    Cardiol Young; 2007 Aug; 17(4):354-5. PubMed ID: 17572938
    [No Abstract]   [Full Text] [Related]  

  • 60. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial.
    Lainchbury JG; Troughton RW; Frampton CM; Yandle TG; Hamid A; Nicholls MG; Richards AM
    Eur J Heart Fail; 2006 Aug; 8(5):532-8. PubMed ID: 16829189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.